LEVAQUIN (Levofloxacin)
Abstract
This chapter provides basic characteristics, FDA-approved indications, side effects/toxicity, dosage information, drug/food interactions and antimicrobial therapy art of LEVAQUIN (Levofloxacin). Levofloxacin inhibits bacterial topoisomerase IV and DNA gyrase. Levofloxacin is indicated for the treatment of serious infections caused by susceptible strains of microorganisms in the diseases listed below: pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis and urinary tract infections. Levofloxacin is contraindicated in persons with a history of hypersensitivity associated with the use of levofloxacin or any quinolone. Levofloxacin tablets can be administered without regard to food. Levofloxacin oral solution should be taken 1 hour before or 2 hours after eating. Levofloxacin is supplied in 250 mg, 500 mg, and 750 mg tablets and an oral solution containing 25 mg/mL. Levofloxacin is also available for intravenous administration.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.